PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis.

Abstract Pretreatment hematologic parameters of the inflammatory response, including lymphocyte, neutrophil, and platelet counts, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio, have emerged as prognostic factors for patients with cancer. This systematic review and meta-analysis aimed to summarize the association between the hematologic markers and prognosis of nasopharyngeal carcinoma (NPC).
PMID
Related Publications

Prognostic Significance of Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio in Patients with Nasopharyngeal Carcinoma.

High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved.

Pretreatment Neutrophil to Lymphocyte Ratio as a Prognostic Predictor of Urologic Tumors: A Systematic Review and Meta-Analysis.

Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma.

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28296774
OWN - NLM
STAT- MEDLINE
DA  - 20170315
DCOM- 20170410
LR  - 20170410
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 11
DP  - 2017 Mar
TI  - Pretreatment hematologic markers as prognostic factors in patients with
      nasopharyngeal carcinoma: A systematic review and meta-analysis.
PG  - e6364
LID - 10.1097/MD.0000000000006364 [doi]
AB  - BACKGROUND: Pretreatment hematologic parameters of the inflammatory response,
      including lymphocyte, neutrophil, and platelet counts, neutrophil-to-lymphocyte
      ratio (NLR), lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio, have
      emerged as prognostic factors for patients with cancer. This systematic review
      and meta-analysis aimed to summarize the association between the hematologic
      markers and prognosis of nasopharyngeal carcinoma (NPC). METHODS: A systematic
      search of PubMed, Google Scholar, MEDLINE, EMBASE, Web of Science, and the
      Cochrane Library was conducted up to April 2016. Hazard ratios (HRs) with 95%
      confidence intervals (95% CIs) were extracted and synthesized to examine
      prognostic outcomes including cancer-specific survival (CSS), overall survival
      (OS), progression-free survival (PFS), distant metastasis-free survival, and
      local relapse-free survival (LRFS). RESULTS: Fourteen studies comprising 11,651
      NPC patients were ultimately included, and all eligible studies were conducted in
      East Asia. The OS, CSS, PFS, distant metastasis-free survival, and LRFS risks
      differed among patients according to hematologic marker levels. All of the
      parameters were associated with prognostic outcomes in patients with NPC. NLR and
      lymphocyte counts were most commonly reported. A high NLR was significantly
      associated with poor NPC prognosis (pooled HR 1.42, 95% CI 1.21-1.67 for CSS;
      pooled HR 1.77, 95% CI 1.41-2.23 for OS; pooled HR 1.67, 95% CI 1.36-2.06 for
      PFS; pooled HR 1.64, 95% CI 1.15-2.34 for LRFS). High lymphocyte count indicated 
      favorable NPC prognosis (pooled HR 0.72, 95% CI 0.64-0.81 for OS; pooled HR 0.71,
      95% CI 0.56-0.91 for PFS). CONCLUSIONS: Meta-analysis indicated that NLR and
      lymphocyte counts could be prognostic predictors in NPC for East Asian
      population. Patients with a high NLR or low lymphocyte count had poor prognosis. 
      However, due to the limitation of included population, the conclusion was limited
      to East Asian patients only.
FAU - Su, Li
AU  - Su L
AD  - aDepartment of Radiation Oncology, First Affiliated Hospital of Fujian Medical
      University bKey Laboratory of Radiation Biology (Fujian Medical University),
      Fujian Province University cFujian Key Laboratory of Individualized Active
      Immunotherapy, Fujian Medical University, Fuzhou, Fujian, China.
FAU - Zhang, Mingwei
AU  - Zhang M
FAU - Zhang, Weijian
AU  - Zhang W
FAU - Cai, Chuanshu
AU  - Cai C
FAU - Hong, Jinsheng
AU  - Hong J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Inflammation Mediators)
RN  - Nasopharyngeal carcinoma
SB  - AIM
SB  - IM
MH  - Asian Continental Ancestry Group
MH  - Biomarkers, Tumor
MH  - Hematologic Tests/*statistics & numerical data
MH  - Humans
MH  - Inflammation Mediators/*blood/metabolism
MH  - Lymphocyte Count
MH  - Nasopharyngeal Neoplasms/*blood/mortality/*pathology
MH  - Neoplasm Recurrence, Local
MH  - Neutrophils/metabolism
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Survival Analysis
PMC - PMC5369929
EDAT- 2017/03/16 06:00
MHDA- 2017/04/11 06:00
CRDT- 2017/03/16 06:00
AID - 10.1097/MD.0000000000006364 [doi]
AID - 00005792-201703170-00055 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Mar;96(11):e6364. doi: 10.1097/MD.0000000000006364.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>